Replimune Group Inc [REPL] stock is trading at $11.06, up 2.31%. An important factor to consider is whether the stock is rising or falling in short-term value. The REPL shares have gain 25.68% over the last week, with a monthly amount glided 16.91%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Piper Sandler started tracking the stock with Overweight rating on November 19, 2021, and set its price target to $52. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $60 on November 17, 2020. Jefferies initiated its recommendation with a Buy and recommended $67 as its price target on November 02, 2020. H.C. Wainwright upgraded its rating to Buy for this stock on October 15, 2020, and upped its price target to $54. In a note dated July 01, 2020, H.C. Wainwright downgraded an Neutral rating on this stock but restated the target price of $25.
Replimune Group Inc [REPL] stock has fluctuated between $4.92 and $22.21 over the past year. Currently, Wall Street analysts expect the stock to reach $24.2 within the next 12 months. Replimune Group Inc [NASDAQ: REPL] shares were valued at $11.06 at the most recent close of the market. An investor can expect a potential return of 118.81% based on the average REPL price forecast.
Analyzing the REPL fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.49 and Total Capital is -0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.72 points at the first support level, and at 10.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.36, and for the 2nd resistance point, it is at 11.66.
Ratios To Look Out For
For context, Replimune Group Inc’s Current Ratio is 10.72. On the other hand, the Quick Ratio is 10.72, and the Cash Ratio is 1.84.
Transactions by insiders
Recent insider trading involved Xynos Konstantinos, Chief Medical Officer, that happened on Jun 07 ’24 when 15881.0 shares were sold. Executive Chairman, Astley-Sparke Philip completed a deal on May 16 ’24 to sell 37928.0 shares. Meanwhile, Chief Executive Officer Patel Sushil sold 20194.0 shares on May 16 ’24.
